$1.33
+0.02 (+1.53%)
Open$1.33
Previous Close$1.31
Day High$1.33
Day Low$1.31
52W High$1.96
52W Low$1.17
Volume—
Avg Volume24.5K
Market Cap65.46M
P/E Ratio—
EPS$-0.24
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+2,042.9% upside
Current
$1.33
$1.33
Target
$28.50
$28.50
$17.57
$28.50 avg
$41.49
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 408.5K | 11.04M | 11.56M |
| Net Income | -12,034,594 | -536,425 | -578,623 |
| Profit Margin | -2,928.8% | -4.9% | -5.0% |
| EBITDA | -13,304,503 | -810,707 | -735,622 |
| Free Cash Flow | — | -370,627 | -351,629 |
| Rev Growth | — | +9.7% | -0.5% |
| Debt/Equity | — | 0.96 | 0.89 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |